Literature DB >> 9066360

Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions.

S Narayanan1, L Fu, E Pioro, N De Stefano, D L Collins, G S Francis, J P Antel, P M Matthews, D L Arnold.   

Abstract

We performed magnetic resonance imaging and magnetic resonance spectroscopic imaging on 28 patients with multiple sclerosis stratified for disability and clinical course (relapsing with at least partial remissions or secondary progressive disease). Lesions were segmented on the conventional proton density and T2-weighted magnetic resonance images, and lesion distribution images were generated for, each patient. The conventional magnetic resonance and spectroscopic images were transformed into a standard brain-based stereotaxic coordinate space, allowing comparison of images from different patients on a voxel-by-voxel basis. The spatial distribution of lesions in the transformed magnetic resonance images did not differ significantly between the relapsing and the progressive disease groups. We then generated from the individual data sets, group lesion probability distribution images for the relapsing and the progressive disease groups. The spatial distribution of metabolites was characterized with respect to lesion distribution using the magnetic resonance spectroscopic images transformed into stereotaxic space and averaged. The neuronal marker N-acetylaspartate was diffusely lower in the multiple sclerosis patients than in normal control subjects. Comparison of the averaged metabolite and T2-weighted lesion probability images confirmed loss of N-acetylaspartate in regions of both high and low lesion probability. This suggests that diffuse axonal volume loss or dysfunction extends beyond the inflammatory lesions of multiple sclerosis, perhaps due to microscopic disease or wallerian degeneration along projection pathways of axons traversing the lesions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066360     DOI: 10.1002/ana.410410314

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  58 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

Review 2.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

3.  Axon reactions precede demyelination in experimental models of multiple sclerosis.

Authors:  E Zapryanova; O S Sotnikov; S S Sergeeva; D Deleva; A Filchev; B Sultanov
Journal:  Neurosci Behav Physiol       Date:  2004-05

Review 4.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

5.  Absence of perforin expression confers axonal protection despite demyelination.

Authors:  Charles L Howe; Jaimie D Adelson; Moses Rodriguez
Journal:  Neurobiol Dis       Date:  2006-11-16       Impact factor: 5.996

6.  Focal neurologic deficit.

Authors:  F J Wippold
Journal:  AJNR Am J Neuroradiol       Date:  2008-11       Impact factor: 3.825

Review 7.  Estrogen and testosterone therapies in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

8.  Nonrigid registration of multiple sclerosis brain images using lesion inpainting for morphometry or lesion mapping.

Authors:  Michaël Sdika; Daniel Pelletier
Journal:  Hum Brain Mapp       Date:  2009-04       Impact factor: 5.038

Review 9.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  Axonal degeneration and progressive neurologic disability in multiple sclerosis.

Authors:  Carl Bjartmar; Bruce D Trapp
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.